MARLBOROUGH, Mass.,
July 2, 2014 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced the official opening of its new
office and laboratory in the Marlborough Technology Center. The
Company will host a ribbon-cutting ceremony on Wednesday, July 9, 2014 from 10:00 -12:00 p.m., at 257 Simarano Drive,
Marlborough, MA, to mark the
opening of their new facility. The ceremony will be held in
collaboration with the Massachusetts Life Sciences Center (MLSC)
and MassBio.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"The Company's recent move to Marlborough has allowed us to centralize our
employee base," said Dr. Geert
Cauwenbergh, President and CEO of RXi Pharmaceuticals. "In
addition, this facility allows for future growth considerations as
we advance our pre-clinical and clinical programs."
RXi Pharmaceuticals was founded in 2011. Since that time, the
Company has successfully completed and announced positive results
from two Phase 1 clinical studies with our lead compound
RXI-109. We have formed two therapeutic franchises, within
RXi, based on our areas of focus: Dermatology and
Ophthalmology. The Company has continued to progress its dermal
clinical program and is currently conducting two Phase 2 studies
with a third study planned for initiation this year. Within our
Ophthalmology program, we have obtained positive results, with
RXI-109, in the eyes of cynomolgus monkeys. In addition, the
Company received a notice of allowance from the United States
Patent and Trademark Office (USPTO) for a key patent covering our
core, self-delivering RNAi technology (sd-rxRNA®) platform, which
sets us apart from the competition and provides us with a powerful
advantage to deliver our RNAi compounds without delivery
vehicles. We believe we are well positioned for continued
success.
The Company is supported by a group of dedicated, professional
employees, with strategic guidance provided by a seasoned and
successful Board of Directors, and by an accomplished Management
and Scientific Advisory Board with significant experience in RNAi
therapeutics, dermatology drug development and in building and
managing emerging life science companies.
"Thanks to our growth strategy of investing in education,
innovation and infrastructure, Massachusetts continues to lead the world in
life sciences," said Massachusetts
Governor Deval Patrick. "We
congratulate RXi Pharmaceuticals on their expansion and look
forward to their continued contributions to our thriving life
sciences community."
"On behalf of the Center, I would like to extend our warmest
congratulations to RXi Pharmaceuticals as the company officially
opens its new office and laboratory in Marlborough," said Susan Windham Bannister, Ph.D., President and
CEO of the Massachusetts Life Sciences Center, the agency charged
with implementing Governor Patrick's 10-year, $1 billion Life Sciences Initiative. "We've
enjoyed a long-standing relationship with RXi, and we are pleased
to celebrate its ongoing success and growth in Massachusetts."
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an investment
agency that supports life sciences innovation, research,
development and commercialization. The MLSC is charged with
implementing a 10-year, $1-billion,
state-funded investment initiative. These investments create jobs
and support advances that improve health and well-being. The MLSC
offers the nation's most comprehensive set of incentives and
collaborative programs targeted to the life sciences ecosystem.
These programs propel the growth that has made Massachusetts the global leader in life
sciences. The MLSC creates new models for collaboration and
partners with organizations, both public and private, around the
world to promote innovation in the life sciences. For more
information, please visit www.masslifesciences.com.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of
their ability to down-regulate the expression of specific genes
that may be over-expressed in disease conditions. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, entered into human clinical trials in June 2012 and is currently being evaluated in
Phase 2 clinical trials to reduce dermal scarring (fibrosis).
RXI‑109 targets connective tissue growth factor (CTGF), which may
also be key in the development of retinal scarring. RXi's
sd‑rxRNA oligonucleotides are designed for therapeutic use and have
drug-like properties, such as high potency, target specificity,
serum stability, reduced immune response activation, and efficient
cellular uptake. These hybrid oligonucleotide molecules combine the
beneficial properties of conventional RNAi and antisense
technologies. This allows sd‑rxRNAs to achieve efficient
cellular uptake and potent, long-lasting intracellular activity.
For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks and
uncertainties: the risk that we may not be able to
successfully develop our candidates, or that development of
RNAi-based therapeutics may be delayed or not proceed as planned,
or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed,
risks related to the development and commercialization of products
by our competitors, the risk related to our ability to control the
timing and terms of collaborations with third parties, and the
possibility that other companies or organizations may assert patent
rights preventing us from developing our products. Actual results
may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
For additional details or to attend the ceremony, please
contact:
RXi
Pharmaceuticals
Tamara
McGrillen
Phone:
508-929-3646
Email:
tmcgrillen@rxipharma.com
|
MLSC
Angus
McQuilken
Phone:
617-921-7749
Email:
amcquilken@masslifesciences.com
|
RXi Pharmaceuticals' new facility is located at the following
address:
257 Simarano Drive, Suite 101
Marlborough, MA 01572
Phone: 508-767-3861
Email:
admin@rxipharma.com
This announcement is not intended to be a commercial
endorsement by the MLSC of any products or services provided or
developed by the entities referenced in this release.
SOURCE RXi Pharmaceuticals Corporation